In Brief: Genta
Genta: Restructures operations to focus on near-term drug delivery development pipeline and "Anticode" cancer program, the San Diego-based company announces March 16. In reaction to constraints in the financial market and to reduce its burn rate, Genta has cut its research personnel by 25% since the beginning of 1995. The Anticode cancer program recently announced positive results in preclinical trials and will be moving into clinical trials in the U.K. in 1995. The company is pursuing corporate partners for development of dermatology products now in Phase II trials and for marketing Actagen, for which Genta will submit a marketing application in France this year...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth